Business
Grant of share options, issue of equity and TVR
Grant of share options, issue of equity and TVR.
About this update from Theracryf Plc
[{"type":"text","content":"\n \nRNS Number : 1353U Evgen Pharma PLC 10 July 2018 \n\n10 July 2018\n \nEvgen Pharma plc\n \n(\"Evgen\" or \"the Company\")\n \nGrant of share options, issue of equity and total voting rights\n \n \nEvgen (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions announces that Sally Ross, the Company's Clinical Development Officer, has been granted nil cost options over a total of 368,304 ordinary shares in the Company. The options are exercisable, subject to the option vesting, for a period of up to ten years from the date of grant under the Evgen Pharma plc Long Term Incentive Plan (\"LTIP\"). \nThe number of nil cost options awarded has been calculated by reference to the three month average share price to 3 July 2018. These nil cost options are subject to the rules of the LTIP and will vest based on share price performance between the date of grant and the third anniversary of grant. \nIssue of Equity \nIn addition, the Company announces that it has received a notice to exercise options over 80,000 ordinary shares in the Company. The options were granted under an individual option agreement and have an exercise price of 7.3 pence per share. Accordingly, the Company has issued and allotted 80,000 new ordinary shares of 0.25 pence each (\"New Ordinary Shares\"). The New Ordinary Shares rank pari passu with the Company's existing issued ordinary shares. Application has been made to admit the New Ordinary Shares to trading on AIM and dealings in these shares are expected to commence at 8.00 a.m. on 12 July 2018. \nTotal Voting Rights \nThere are no shares held in treasury, therefore following the admission of the New Ordinary Shares the total number of voting rights in the Company will be 93,356,858. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest under the Disclosure and Transparency Rules.\n \nEnquiries:\n \n\n\n\n\nEvgen Pharma plc\nDr Stephen Franklin, CEO\nRichard Moulson, CFO\n\n\n+44 (0) 01625 466591\n\n\n\n\nBuchanan\nMark Court, Sophie Cowles, Stephanie Watson\n\n\n+44 (0) 20 7466 5000\n\n\n\n\nNorthland Capital Partne...